Apixaban and Vilazodone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Vilazodone
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Taking these together can raise your chance of bleeding. Vilazodone (Viibryd) is an antidepressant that affects a chemical called serotonin. Serotonin also helps your platelets (the cells that form clots) work properly. Apixaban (Eliquis) is a blood thinner. When you use both, their effects can add up and make bleeding a little more likely.
This concern is based mostly on how the drugs work in theory, not on strong studies, so try not to worry. Just watch for things like easy bruising, nosebleeds, bleeding gums, or unusual bleeding, and tell your doctor if you notice them. Your care team can safely manage this combination.
Effect: Additive bleeding risk with concurrent vilazodone and apixaban.
Mechanism: SSRIs/SSRI-like agents deplete platelet serotonin, impairing serotonin-mediated platelet aggregation. Combined with apixaban's direct factor Xa inhibition, this produces additive/pharmacodynamic effects on hemostasis. Neither agent depends on the other for activation.
- Direction: Increased bleeding risk (PD interaction, no PK/AUC change expected)
- Onset: Unspecified
- Evidence: Theoretical
- Severity: Major
Management: Use caution. Counsel on bleeding signs, monitor for hematologic/GI bleeding, and individualize therapy. Consider closer follow-up in higher-risk patients.
What happens
An increased risk of bleeding
Interaction Deep Dive
Exercise caution when vilazodone is given together with anticoagulant or antiplatelet drugs, since combined use may raise the likelihood of bleeding312. A possible mechanism is vilazodone's influence on platelet serotonin release. Patients should be advised of the heightened bleeding risk that accompanies taking vilazodone alongside antiplatelet agents or anticoagulants1.
Why it happens (mechanism)
Release of serotonin by platelets; additive effects on hemostasis
How to manage this interaction
Keep taking both medications as prescribed unless your doctor tells you otherwise. This combination can usually be managed safely with awareness and monitoring.
- Watch for signs of bleeding: unusual bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, or bleeding that won't stop.
- Report any of these to your pharmacist or doctor promptly.
- Your care team may monitor you more closely and will tailor your treatment to your personal bleeding risk.
- Tell your providers about all other medicines, including aspirin, NSAIDs (like ibuprofen), and supplements, since these can add to bleeding risk.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) In a retrospective study involving patients older than 50 years diagnosed with acute myocardial infarction (N=27,058), the use of an SSRI together with any antiplatelet therapy raised the risk of bleeding significantly, by 1.42-fold, relative to aspirin used alone. Combined treatment with aspirin, clopidogrel, and an SSRI significantly elevated risk by 2.35-fold compared with aspirin alone and by 1.57-fold compared with the combination of clopidogrel and aspirin 2.
b) In a systematic review and meta-analysis covering 22 observational studies, SSRI use was linked to a significant 1.55-fold rise in the risk of upper gastrointestinal bleeding (UGIB). The simultaneous use of SSRIs with antiplatelet drugs was linked to a 2.48-fold rise in UGIB risk (3 studies) 3.
c) Case-control and cohort studies have demonstrated that using selective serotonin and norepinephrine reuptake inhibitors (such as vilazodone) together with antiplatelet agents has been linked to a greater risk of gastrointestinal bleeding. Drawing on data from published observational studies, exposure to SSRIs, especially during the month preceding delivery, has been linked to a less than 2-fold rise in the risk of postpartum hemorrhage. Reported bleeding events have included epistaxis, ecchymosis, hematoma, petechiae, and life-threatening hemorrhages 1.
Common questions
Can I take Apixaban and Vilazodone together?
Using vilazodone with apixaban can add up to a higher bleeding risk, so watch for unusual bleeding or bruising and report it. Keep taking both as prescribed and let your care team monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Vilazodone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Vilazodone interaction managed?
Keep taking both medications as prescribed unless your doctor tells you otherwise. This combination can usually be managed safely with awareness and monitoring. Watch for signs of bleeding: unusual bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, or bleeding that won't stop. Report any of these to your pharmacist or doctor promptly. Your care team may monitor you mor… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Vilazodone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: VIIBRYD(R) oral tablets, vilazodone HCl oral tablets. Allergan USA Inc (per FDA), Madison, NJ, 2023. DailyMed
- Labos C, Dasgupta K, Nedjar H, et al: Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183(16):1835-1843. PubMed
- Jiang HY, Chen HZ, Hu XJ, et al: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13(1):42-50. DOI
Keep reading about Vilazodone
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist